[The effect of administering Omega-3 acids on lipids in serum, functional state of erythrocyte membrane and function of the kidneys in patients with primary glomerulonephritis].
There are reports concerning profitable influence of unsaturated acids administration on blood pressure, inflammation and proteinuria. The aim of presented study was to estimate the effect of Omega-3 on plasma lipids and renal function in patients with primary glomerulopathies. The tested group consisted of 13 patients (7F and 6M) aged from 22 to 60 years, with primary glomerulopathies and normal renal function. They received Omega-3 (Fishproduct, iceland) 3 x 2 caps for three months. Before, after 2 and 3 months of treatment and 3 months after its discontinuation following parameters were estimated: total cholesterol, HDL and LDL cholesterol (HDL, LDL), triglycerides and an order parameter of erythrocyte lipid bilayer (S). Simultaneously N-acetylglutamate (NAG), creatinine clearance and 24-hours proteinuria were measured. For calculation t-Student test was used. In our study we found statistically significant increase of HDL after 2 and 3 months and decrease of LDL after 3 months of Omega-3 administration (p < 0.05). During the 2 and 3 months of treatment statistically significant decrease of NAG was noticed but a month after its discontinuation significant increase of NAG excretion was observed (p < 0.05). The S parameter in tested group of patients was higher than in healthy population but during Omega-3 administration the value of an order parameter of erythrocyte bilayer increased significantly (p < 0.01). On the base of given results we could conclude that unsaturated acids may have profitable influence on plasma lipids, functional status of erythrocyte membrane and probably proximal tubule function in patients with primary glomerulopathies.
Fox
J
J
Kliniki Chorób Nerek Instytutu Chorób Wewnetrznych AMG.
Manitius
J
J
Debska-Slizień
A
A
Rutkowski
B
B
Nowak
J
J
Bautembach
S
S
Owczarzak
A
A
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004910:Erythrocyte Membrane / Q000187:drug effects*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage* / Q000502:physiology; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D005971:Glutamates / Q000652:urine; D006801:Humans; D007249:Inflammation / Q000517:prevention & control; D007668:Kidney / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000517:prevention & control
D015525:Fatty Acids, Omega-3; D005971:Glutamates; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; C016195:N-acetylglutamic acid
Wpływ podawania kwasów Omega-3 na zachowanie sie lipidów w surowicy krwi, stan czynnościowy błony erytrocyta oraz funkcje nerek u pacjentów z pierwotnymi kłebuszkowymi zapaleniami nerek.